The progression of liver disease to liver cancer is primarily monitored by serum levels of the oncofetal glycoprotein, alpha-fetoprotein (AFP), or the core fucosylated glycoform of AFP, AFP-L3. The gene discussed is AFP; the disease is liver disorder.